Biodesix Earnings Call Transcripts
Fiscal Year 2026
-
The company is expanding its lung diagnostics platform, leveraging genomics, proteomics, and radiomics to improve patient outcomes and operational efficiency. Strong sales growth, high gross margins, and a robust development pipeline support its focus on sustainable profitability and market expansion.
-
The company is expanding its lung diagnostics business, targeting both pulmonologists and primary care to address a large, underserved market. Strong real-world evidence, robust sales force productivity, and strategic partnerships support growth, while financial discipline and recent capital raises have strengthened the balance sheet.
Fiscal Year 2025
-
Q4 2025 saw 41% revenue growth and first-ever positive adjusted EBITDA, driven by lung diagnostics and expanded sales reach. 2026 guidance projects 23% revenue growth, with continued margin strength and operational leverage. Cash position strengthened by new financing and loan extension.
-
Q3 2025 saw 20% revenue growth, improved gross margins, and strong expansion in primary care and development services. Raised full-year guidance to $84–$86 million, with Adjusted EBITDA positivity expected in Q4. Clinical and commercial momentum continues.
-
The company is expanding its lung cancer diagnostic platform by integrating primary care referrals and growing its sales force, while digital ordering and biopharma partnerships drive operational and revenue gains. Ongoing clinical studies and collaborations with leading institutions support future growth and potential guideline inclusion.
-
Q2 2025 revenue grew 12% year-over-year to $20M, driven by lung diagnostics and development services. Gross margin rose to 80%, and primary care test orders more than doubled. The company expects to reach adjusted EBITDA positivity in Q4, maintaining $80–$85M revenue guidance.
-
A leading lung diagnostics company highlighted strong revenue growth, industry-leading margins, and a robust clinical pipeline at the conference. Expansion into digital diagnostics, primary care outreach, and new partnerships are expected to drive further growth.
-
Q1 2025 revenue grew 21% year-over-year, driven by lung diagnostics and development services, with gross margin rising to 79.4%. Sales team reconfiguration delayed commercial expansion, prompting revised annual revenue guidance to $80–$85 million, but adjusted EBITDA positivity is still expected in Q4.
-
2025 is positioned as a transformative year, with strong growth, high gross margins, and a major sales force expansion. Key catalysts include new clinical data, HEDIS measure rollout, and anticipated guideline updates, all supporting further market penetration and financial milestones.
Fiscal Year 2024
-
2024 revenue grew 45% to $71.3M, with gross margin rising to 78% and adjusted EBITDA loss improving 32%. 2025 guidance targets $92–$95M revenue, sustained high margins, and adjusted EBITDA profitability, driven by lung diagnostics and expanded sales force.
-
Q3 2024 saw 35% revenue growth, strong lung diagnostics performance, and improved margins, despite hurricane-related disruptions. Full-year guidance of $70–$72 million was reaffirmed, with adjusted EBITDA profitability expected in H2 2025.
-
Strong revenue and margin growth is driven by Nodify tests and expanding payer coverage, with a growing sales force and robust biopharma services pipeline. Updated guidance reflects confidence in maintaining rapid growth, while profitability and new pipeline test launches are prioritized for the future.
-
Q2 2024 saw 51% revenue growth year-over-year, driven by strong lung diagnostics and biopharma services, with gross margins at 78.4%. Revenue guidance for 2024 was raised to $70M–$72M, and the sales force is expanding to support continued growth.
-
Strong growth continues with seven quarters of 50%+ test volume increases and industry-leading margins. The portfolio addresses critical lung cancer diagnostic needs, with rapid test turnaround and a robust pipeline. Biopharma partnerships and a recent $55M fundraise support expansion.
-
Strong growth continues with industry-leading margins and a fully integrated, expanding sales force. Five on-market lung cancer tests drive performance, with Nodify reducing unnecessary procedures by 74%. Pipeline innovation and biopharma partnerships support long-term expansion.